Mokosak Advisory Group LLC Has $290,000 Stake in Amgen Inc. (NASDAQ:AMGN)

Mokosak Advisory Group LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 7.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 927 shares of the medical research company’s stock after buying an additional 64 shares during the period. Amgen makes up 0.1% of Mokosak Advisory Group LLC’s investment portfolio, making the stock its 26th largest holding. Mokosak Advisory Group LLC’s holdings in Amgen were worth $290,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of AMGN. Vanguard Group Inc. lifted its stake in Amgen by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 52,088,210 shares of the medical research company’s stock valued at $14,809,720,000 after acquiring an additional 3,045,657 shares in the last quarter. Capital International Investors raised its position in shares of Amgen by 547.8% during the 1st quarter. Capital International Investors now owns 7,005,269 shares of the medical research company’s stock valued at $1,991,738,000 after buying an additional 5,923,915 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Amgen by 3.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,564,710 shares of the medical research company’s stock worth $1,890,769,000 after buying an additional 243,720 shares during the last quarter. Royal Bank of Canada grew its stake in shares of Amgen by 14.8% during the fourth quarter. Royal Bank of Canada now owns 5,831,624 shares of the medical research company’s stock valued at $1,679,625,000 after buying an additional 751,947 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Amgen in the fourth quarter worth approximately $1,556,912,000. 76.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on AMGN shares. Bank of America lifted their price target on shares of Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 target price (up from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. TD Cowen increased their price objective on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Barclays upgraded Amgen from an “underweight” rating to an “equal weight” rating and lifted their target price for the company from $230.00 to $300.00 in a research report on Friday, May 3rd. Finally, Mizuho increased their price objective on shares of Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a research note on Thursday, May 9th. Eleven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $326.89.

Amgen Price Performance

AMGN stock traded up $4.27 during trading on Friday, hitting $328.80. 1,771,092 shares of the company’s stock traded hands, compared to its average volume of 2,582,902. The business has a fifty day simple moving average of $322.70 and a 200 day simple moving average of $299.51. Amgen Inc. has a 52 week low of $248.38 and a 52 week high of $346.85. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42. The stock has a market capitalization of $176.38 billion, a price-to-earnings ratio of 46.97, a P/E/G ratio of 2.78 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 156.21% and a net margin of 12.74%. The company had revenue of $8.39 billion during the quarter, compared to the consensus estimate of $8.35 billion. During the same quarter in the prior year, the business earned $5.00 earnings per share. The firm’s quarterly revenue was up 20.1% compared to the same quarter last year. As a group, research analysts expect that Amgen Inc. will post 19.5 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were issued a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 annualized dividend and a dividend yield of 2.74%. Amgen’s payout ratio is 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.